Effects of Sitagliptin on 24-H Glycemic Changes in Japanese Patients with Type 2 Diabetes Assessed Using Continuous Glucose Monitoring

Mori, Yutaka; Taniguchi, Yukiko; Matsuura, K.; Sezaki, Kazunori; Yokoyama, Jun′ichi; Utsunomiya, Kazunori

doi:10.1089/dia.2011.0025

Cited by 25 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the number of subjects enrolled was relatively small. The number of subjects studied in some clinical previous investigations (Mori et al, 7 Osonoi et al, 26 and Kim et al 27 ) of glucose fluctuations affected by antidiabetes drugs using CGM was similar to that of our study. Therefore, 26 patients might be enough to verify the effects of teneligliptin on glucose fluctuation using CGM such as in our pilot study.…”

supporting

confidence: 88%

“…5,6 Therefore, DPP-4 inhibitors, incretin-based agents, are a promising new class of antidiabetes drug that can improve glucose fluctuations in patients with type 2 diabetes. 7 Teneligliptin, a novel DPP-4 inhibitor, is substantially metabolized in the liver, and its concentration in the serum is not affected even by severe renal impairment. 8 This suggests that teneligliptin can be administered to patients with renal impairment due to diabetic nephropathy without the need for dose adjustments.…”

Section: Introductionmentioning

confidence: 99%

“…[15][16][17] Advantages of combination therapy with insulin and a DPP-4 inhibitor, such as sitagliptin, include not only an improvement in glycemic control, but also prevention of weight gain, resulting in alleviation of the psychological stress that often occurs when insulin therapy is started. 7,15 The use of teneligliptin as add-on therapy to other antidiabetes drugs was approved in December 2013 in Japan. So far, no reports have shown the efficacy of combination therapy of teneligliptin and insulin in patients with type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy

Tanaka

Suzuki

Aoki

et al. 2014

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Background: This study investigated whether teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, ameliorated glucose fluctuations in hospitalized Japanese patients with type 2 diabetes receiving insulin therapy, with or without other antidiabetes drugs, and using continuous glucose monitoring (CGM). Patients and Methods: Twenty-six patients with type 2 diabetes were admitted for glycemic control. After admission, patients continued to be treated with optimal dietary therapy plus insulin therapy, with or without other antidiabetes drugs, until they achieved stable glycemic control. CGM measurements were made for 7 consecutive days. On Days 1-3, patients received insulin with or without other antidiabetes drugs, and on Days 4-7, teneligliptin 20 mg once daily at breakfast was added to ongoing therapy. Doses of insulin were fixed during the study. Levels of serum glycated albumin (GA), 1,5-anhydro-d-glucitol (1,5-AG), and high-sensitivity C-reactive protein (hsCRP) were measured. Results: Add-on treatment with teneligliptin led to significant improvements in 24-h mean glucose levels, the proportion of time in normoglycemia, mean amplitude of glycemic excursions, and total area under the curve within 2 h after each meal. The proportion of time in hypoglycemia and hsCRP levels did not increase significantly compared with before teneligliptin. Values of 1,5-AG and GA were significantly improved by treatment with teneligliptin. Conclusions: Addition of teneligliptin to insulin therapy led to a significant improvement in diurnal glycemic control and significant reductions in glucose fluctuations in 24-h periods without increasing hypoglycemia in Japanese patients with type 2 diabetes on insulin therapy, with or without other antidiabetes agents.

show abstract

supporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy

Tanaka

Suzuki

Aoki

et al. 2014

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Therefore, we considered that MAGE was likely to make a more significant difference than SD. In this regard, postprandial hyperglycemia is considered to be due to the synergetic effects of gradual glucose absorption of α-GI and improvement of early-stage insulin secretion by glinide [21]. As it has been reported that MIT/VOG improves glycemic control in terms of medication adherence [22], the use of MIT/VOG, which is considered to act as both α-GI and glinide, is considered significant.…”

Section: Discussionmentioning

confidence: 99%

Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes

Arao

Okada

Torimoto

et al. 2017

J UOEH

View full text Add to dashboard Cite

: We analyzed the effects of 100 mg/day sitagliptin and a switch to mitiglinide calcium hydrate/voglibose compound tablets (MIT/VOG) in patients with type 2 diabetes mellitus (T2DM) treated with 50 mg/day sitagliptin. Five patients with T2DM treated with 50 mg/day sitagliptin and hemoglobin A1c (HbA1c) of ≥6.5% were switched to MIT/VOG, or the dose of sitagliptin was increased to 100 mg/day. The effects of the changes in therapy were compared in a crossover fashion by continuous glucose monitoring. The primary endpoint was mean amplitude of glycemic excursions (MAGE), and the secondary end points were 24-hour mean blood glucose level and mean blood glucose level from 0:00 a.m. to 7:00 a.m. and from 7:00 a.m. to 0:00 a.m., percentage of time with blood glucose level of ≥200 mg/ dl and <70 mg/dl, maximum and minimum blood glucose levels, and increases in postprandial blood glucose levels. MAGE was significantly lower with MIT/VOG (P = 0.016), whereas mean blood glucose levels were lower between 0:00 a.m. and 7:00 a.m. with 100 mg/day sitagliptin. The percentage of time with blood glucose level ≥200 mg/dl was significantly shorter with MIT/VOG (P = 0.041). The maximum blood glucose level was significantly lower with MIT/VOG (P = 0.043), and the minimum was significantly lower with 100 mg/day sitagliptin (P = 0.043). Blood glucose levels after dinner and mean increases in postprandial blood glucose levels were significantly lower with MIT/ VOG (P = 0.090 and P = 0.045 respectively). In patients with T2DM, treatment with MIT/VOG improves MAGE and postprandial hyperglycemia and 100 mg/day sitagliptin lowers early morning glucose levels. This trial was registered with the University Hospital Medical Information Network (UMIN) (No. UMIN R000008274).

show abstract

“…In 2009, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin was approved as the first incretin enhancer for use in Japan [4][5][6][7][8][9][10][11] . Although it has been suggested that seasonal fluctuations of hemoglobin A1c (HbA1c) are noted in patients with type 2 diabetes, no reports have been published concerning the efficacy of antidiabetic agents for such fluctuations.…”

Section: Introductionmentioning

confidence: 99%

Sitagliptin counteracts seasonal fluctuation of glycemic control

Matsuhashi

Sano²,

Fukuda³

et al. 2012

WJD

View full text Add to dashboard Cite

AIM:To assess the effect of sitagliptin therapy on seasonal fluctuation of glycemic control in Japanese type 2 diabetic patients. METHODS:Participating patients (age: 29-80 years) had been treated with conventional oral antidiabetic agents and/or diet and exercise therapy for over 6 mo. From December 2009, 35 patients were additionally prescribed oral sitagliptin starting from 50 mg once daily, while 19 patients taking α-glucosidase inhibitors were switched to sitagliptin. Twenty-four patients who refused sitagliptin formed the control group. Changes of mean monthly hemoglobin A1c (HbA1c) during the "winter holiday season" were compared between groups using Student's t -test (2008-2009 vs 2009-2010). Statistical significance was accepted at � < 0.05. �ulti�ariate 0.05. �ulti�ariate analysis was performed to assess whether sitagliptin use was associated with deterioration or improvement of glycemic control. RESULTS:Both add-on sitagliptin and switching from α-glucosidase inhibitors to sitagliptin prevented the seasonal deterioration of glycemic control and tended to improve HbA1c. Multivariate analysis revealed that both adding and switching to sitagliptin were negatively correlated with deterioration of glycemic control. In 44 patients who continued sitagliptin therapy for another year, elevation of HbA1c was suppressed without adverse effects. CONCLUSION:Sitagliptin is a suitable oral agent for preventing deterioration of glycemic control during the winter holiday season.

show abstract

Effects of Sitagliptin on 24-H Glycemic Changes in Japanese Patients with Type 2 Diabetes Assessed Using Continuous Glucose Monitoring

Abstract: Sitagliptin decreased the average glycemic level and also improved 24-h glycemic fluctuation, including postprandial hyperglycemia.

Cited by 25 publications

References 19 publications

Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy

Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy

Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes

Sitagliptin counteracts seasonal fluctuation of glycemic control

Contact Info

Product

Resources

About